EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The effects of omega‐3, DHA , EPA , Souvenaid® in Alzheimer's disease: A systematic review and meta‐analysis

Ernesto Calderon Martinez iD, Stephin Zachariah Saji, Jonathan Victor Salazar Ore, Omar A Borges-Sosa, Samyuktha Srinivas, Naga Sai Rasagna Mareddy, Tanseem Manzoor, Mariela Di Vanna, Yasemin Al Shanableh, Rishabh Taneja, Victor Sebastian Arruarana

Neuropsychopharmacology Reports · 2024-09 · 44 (3) · 545-556

DOI: 10.1002/npr2.12455 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 25.06.2024. Verfasst von Ernesto Calderon Martinez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Digital Health, Universidad Nacional Autónoma de México, Mexico City, Mexico. Hauptthemen laut MEDLINE: Alzheimer Disease, Docosahexaenoic Acids, Fatty Acids, Omega-3, Eicosapentaenoic Acid. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer's disease (AD) is the most common cause of dementia worldwide. Omega‐3 fatty acids (n‐3‐PUFA) are essential to normal neural development and function. Souvenaid®, a medical supplement that contains n‐3‐PUFA's: eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), has emerged as an alternative, slowing cognitive decline in AD patients. In this study, we investigated the effect of dietary supplementation with n‐3‐PUFA, EPA, DHA, and Souvenaid® in AD patients.

Aim

This systematic review and meta‐analysis aim to establish the relationship between n‐3‐PUFA, EPA, DHA, and Souvenaid® with cognitive effects, ventricular volume and adverse events in AD patients.

Methods

A systematic search of randomized control trials (RCT), cohorts, and case–control studies was done in PubMed, Scopus, Web of Science, Cochrane, and Embase for AD adult patients with dietary supplementation with n‐3‐PUFA, EPA, DHA, or Souvenaid® between 2003 and 2024.

Results

We identified 14 studies with 2766 subjects aligned with our criteria. Most publications described positive cognitive outcomes from supplements (58%). The most common adverse events reported were gastrointestinal symptoms. CDR scale showed reduced progression of cognitive decline (SMD = −0.4127, 95% CI: [−0.5926; −0.2327]), without subgroup differences between different dietary supplement interventions. ADCS‐ADL, MMSE, ADAS‐cog, adverse events, and ventricular volume did not demonstrate significant differences. However, Souvenaid® showed a significant negative effect (SMD = −0.3593, 95% CI: −0.5834 to −0.1352) in ventricular volumes.

Conclusions

The CDR scale showed reduced progression of cognitive decline among patients with n‐3‐PUFA supplemental interventions, with no differences between different n‐3‐PUFA supplements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDocosahexaenoic AcidsFatty Acids, Omega-3Eicosapentaenoic AcidDietary SupplementsHumans

Stichwörter der Autor:innen

Alzheimer's diseaseDHAOmega‐3 fatty acidsSouvenaid®cognitive decline

Substanzen

Docosahexaenoic AcidsFatty Acids, Omega-3Eicosapentaenoic AcidSouvenaid

Autor:innen und Institutionen

  • Digital Health, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Our Lady of Fatima University, Valenzuela City, Philippines.
  • Facultad de Ciencias Médicas, Universidad de Buenos Aires, Buenos Aires, Argentina.
  • Indiana University, Bloomington, Indiana, USA.
  • Manipal Academy of Higher Education, Kasturba Medical College, Mangalore, Karnataka, India.
  • Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Ernesto Calderon Martinez

Zitieren

APA

Calderon Martinez, E., Zachariah Saji, S., Salazar Ore, J. V., Borges-Sosa, O. A., Srinivas, S., Mareddy, N. S. R., Manzoor, T., Di Vanna, M., Al Shanableh, Y., Taneja, R., & Arruarana, V. S. (2024). The effects of omega‐3, DHA , EPA , Souvenaid® in Alzheimer's disease: A systematic review and meta‐analysis. Neuropsychopharmacology Reports, 44(3), 545-556. https://doi.org/10.1002/npr2.12455

Vancouver

Calderon Martinez E, Zachariah Saji S, Salazar Ore JV, Borges-Sosa OA, Srinivas S, Mareddy NSR, et al. The effects of omega‐3, DHA , EPA , Souvenaid® in Alzheimer's disease: A systematic review and meta‐analysis. Neuropsychopharmacology Reports. 2024;44(3):545-556. doi:10.1002/npr2.12455

BibTeX
@article{CalderonMartinez2024,
  author = {Calderon Martinez, Ernesto and Zachariah Saji, Stephin and Salazar Ore, Jonathan Victor and Borges-Sosa, Omar A and Srinivas, Samyuktha and Mareddy, Naga Sai Rasagna and Manzoor, Tanseem and Di Vanna, Mariela and Al Shanableh, Yasemin and Taneja, Rishabh and Arruarana, Victor Sebastian},
  title = {The effects of omega‐3, DHA , EPA , Souvenaid® in Alzheimer's disease: A systematic review and meta‐analysis},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  volume = {44},
  number = {3},
  pages = {545--556},
  doi = {10.1002/npr2.12455}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche